Abstract
Toll-like receptor (TLR) agonists have been shown to have anti-tumor activity in basic research and clinical studies. However, TLR agonist monotherapy in cancer treatment dose not sufficiently eliminate tumors. Activation of the innate immune response by TLR agonists and other pathogen-associated molecular patterns is effective for driving adaptive immunity via interleukin (IL)-12 or IL-1, but is counteracted by the simultaneous induction of immunosuppressive cytokines and other molecules, including IL-10, tumor growth factor-β, and induced nitric oxide synthase (iNOS). In the present study, we evaluated the anticancer effect of the TLR7 agonist, imiquimod (IMQ), in the absence of iNOS. The administration of IMQ in iNOS-knockout (KO) mice implanted with tumor cells significantly suppressed tumor progression as compared to that in wild-type mice and improved the survival rate. Moreover, injection with IMQ enhanced the tumor antigen-specific Th1 response in iNOS-KO mice with tumors. The enhancement of the antigen-specific Th1 response was associated with an increase in IL-2 and IL-12b expressions in the tumor-draining lymph nodes. Combination therapy with IMQ and an iNOS inhibitor also significantly inhibited tumor growth in the established tumor model. Finally, our results indicated that the enhancement of iNOS expression through the administration with TLR agonists impairs host anti-tumor immunity, while the inhibition of iNOS could enhance the therapeutic efficacy of TLR agonists via the increase in Th1 immune response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- Ab:
-
Antibody
- DC:
-
Dendritic cell
- DLN:
-
Draining lymph node
- IFN:
-
Interferon
- IL:
-
Interleukin
- IMQ:
-
Imiquimod
- iNOS:
-
Inducible nitric oxide synthase
- KO:
-
Knockout
- L-NAME:
-
NG-nitro-l-arginine methyl ester
- MDSCs:
-
Myeloid-derived suppressor cells
- NO:
-
Nitric oxide
- OVA:
-
Ovalbumin
- TLR:
-
Toll-like receptor
- WT:
-
Wild-type
References
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384
Conroy H, Marshall NA, Mills KH (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27:168–180
Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320
Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F, Qian F (2001) Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 67:709–713
Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41–44
Ochoa AC, Zea AH, Hernandez C, Rodriguez PC (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13:721s–726s
Ito H, Koide N, Morikawa A, Hassan F, Islam S, Tumurkhuu G et al (2005) Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells. J Endotoxin Res 11:213–219
Karlsson A, Jagervall K, Utkovic H, Karlsson L, Rehnstrom E, Fredin MF et al (2008) Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice. Biochem Biophys Res Commun 367:242–248
Ohtaki H, Ito H, Ando K, Ishikawa T, Saito K, Imawari M et al (2009) Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes. Biochem Biophys Res Commun 378:579–583
Shirota H, Klinman DM (2011) CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother 60:659–669
Ito H, Ando T, Ando K, Ishikawa T, Saito K, Moriwaki H et al (2014) Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2,3-dioxygenase activity. Immunology 142:614–623
Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I et al (2006) Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest 86:254–261
Ito H, Ando K, Ishikawa T, Saito K, Takemura M, Imawari M et al (2009) Role of TNF-alpha produced by nonantigen-specific cells in a fulminant hepatitis mouse model. J Immunol 182:391–397
Blasius AL, Beutler B (2010) Intracellular toll-like receptors. Immunity 32:305–315
Connolly DJ, O’Neill LA (2012) New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 12:510–518
Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C (2012) Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 7:29–54
Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146
Ciorba MA, Bettonville EE, McDonald KG, Metz R, Prendergast GC, Newberry RD et al (2010) Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 184:3907–3916
Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W (2003) The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149(Suppl 66):53–56
Weber G, Caruana I, Rouce RH, Barrett AJ, Gerdemann U, Leen AM et al (2013) Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia—implications for immunotherapy. Clin Cancer Res 19:5079–5091
Mortenson ED, Park S, Jiang Z, Wang S, Fu YX (2013) Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res 19:1476–1486
Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S et al (2013) Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother 62:1053–1060
Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K et al (2008) Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol 20:869–879
Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML (1999) Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol 41:1002–1007
Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM et al (2010) Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 184:5360–5367
Blesson S, Thiery J, Gaudin C, Stancou R, Kolb JP, Moreau JL et al (2002) Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 14:1169–1178
Acknowledgments
The authors thank Dr. H. Shirota for kindly providing several of the tumor cell lines in this study. This work was supported by Grant-in-Aid for Scientific Research (C) (24659361) from the Ministry for Education, Culture, Sports, Science and Technology of Japan.
Conflict of interest
The authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ito, H., Ando, T., Ogiso, H. et al. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice. Cancer Immunol Immunother 64, 429–436 (2015). https://doi.org/10.1007/s00262-014-1644-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-014-1644-6